Inflammatory Demyelinating Polyneuropathy
📧 Sign up to get email alerts when something new happens for Inflammatory Demyelinating Polyneuropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP [Phase 3]
An ongoing Phase 3 long-term safety and efficacy study of riliprubart in participants with chronic inflammatory demyelinating polyneuropathy…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 2]
Phase 2 study of IMVT-1402 in adults with Chronic Inflammatory Demyelinating Polyneuropathy is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 3]
A Phase 3 clinical trial investigating the efficacy and safety of Riliprubart versus the usual IVIg treatment in chronic inflammatory demyel…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) [Phase 3]
A Phase 3 clinical trial (CAPTIVATE) evaluating the efficacy and safety of DNTH103 in adults with chronic inflammatory demyelinating polyneu…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases [Phase 1]
A Phase 1 trial evaluating the safety and preliminary efficacy of KITE-363 in relapsed/refractory autoimmune neurologic diseases is currentl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP [Phase 3]
A Phase 3 study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with CIDP is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy [Phase 3]
A Phase 3 study is evaluating the pharmacokinetics and safety of XEMBIFY versus Gamunex-C in participants with CIDP; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP [Phase 2]
A Phase 2 clinical trial assessing the safety, tolerability, and efficacy of NVG-2089 in participants with chronic inflammatory demyelinatin…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 3]
A Phase 3 trial evaluating intravenous immunoglobulin (IGIV) 10% for chronic inflammatory demyelinating polyneuropathy is currently recruiti…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 2, Phase 3]
A Phase 2/3 clinical trial investigating Nipocalimab for adults with chronic inflammatory demyelinating polyneuropathy (CIDP) is currently r…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. [Phase 1]
Phase 1 clinical trial update assessing the safety and pharmacodynamics of QH103 cell injections in relapsed/refractory antibody-mediated ne…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work [Phase 3]
Phase 3 clinical trial evaluating the effects and safety of Riliprubart for chronic inflammatory demyelinating polyneuropathy that does not …
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC [Phase 4]
Phase 4 study evaluating adults with chronic inflammatory demyelinating polyneuropathy transitioning from intravenous immunoglobulin to subc…
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The document describes a pre-approval access program for subcutaneous efgartigimod in adults with chronic inflammatory demyelinating polyneu…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP [Phase 3]
Phase 3 trial evaluating the efficacy and safety of Empasiprubart in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) is…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices
A clinical trial evaluating subcutaneous immunoglobulin therapy for Chronic Inflammatory Demyelinating Polyneuropathy with effectiveness mon…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
This clinical trial update indicates ongoing recruitment for a study evaluating nerve function and structure in Charcot-Marie-Tooth disease …
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases [Phase 2]
Phase 2 clinical trial investigating autologous stem cell transplant for neurologic autoimmune diseases is currently active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
A completed clinical trial investigating whether IgG level fluctuations after initial intravenous immunoglobulin treatment relate to subsequ…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
A worldwide pregnancy safety study is recruiting to assess maternal, fetal, and infant outcomes after exposure to efgartigimod during pregna…
-
EMA approval · 2026-02-11EMA Authorised: HyQvia (human normal immunoglobulin) — Baxalta Innovations GmbH
EMA authorised HyQvia, a subcutaneous immunoglobulin product with recombinant human hyaluronidase, from Baxalta Innovations GmbH for immunod…
-
EMA approval · 2026-01-23EMA Authorised: Vyvgart (efgartigimod alfa) — Argenx
The European Medicines Agency has authorised Vyvgart (efgartigimod alfa) for the treatment of myasthenia gravis and chronic inflammatory dem…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases [EARLY_Phase 1]
An early-phase UCAR-T therapy targeting CD19/BCMA is being evaluated for relapsing or refractory multiple sclerosis, myasthenia gravis, CIDP…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 2]
Open-label extension study of Batoclimab in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) is currently enrolling by i…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases [EARLY_Phase 1]
A Phase 1 trial evaluating a universal CAR T-cell therapy targeting CD19 and BCMA in relapsed/refractory neurological autoimmune diseases, w…